Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2335615 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL8966804 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL18975256 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL135863 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL23014949 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL23014965 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL130671 | 1.00 | — | — | |
| SCHEMBL130493 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL8907249 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL131692 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12429483-B2 | System and method for determining onset and disease progression | RESPIRATION SCAN LTD (IL) | 2025-09-30 | — | — | US | claimed |
| CN-115074079-B | Single-component addition type organic silicon heat-conducting adhesive and preparation method thereof | 天津澳普林特科技股份有限公司 | 2023-12-26 | — | — | CN | claimed |
| CN-114958246-B | Multifunctional auxiliary agent and preparation method thereof | 天津澳普林特科技股份有限公司 | 2023-11-28 | — | — | CN | claimed |
| WO-2023119334-A1 | ANTI-CANCER COMPOUND BY COMBINING PONATINIB MOLECULE WITH HDAC INHIBITOR MOLECULE USING A VARIABLE LENGTH LINKER | AMRITA VISHWA VIDYAPEETHAM (IN) | 2023-06-29 | — | — | WO | claimed |
| US-11198898-B2 | Chemical tools for imaging phospholipase D activity | CORNELL UNIVERSITY (US) | 2021-12-14 | — | — | US | claimed |
| US-20190085373-A1 | CHEMICAL TOOLS FOR IMAGING PHOSPHOLIPASE D ACTIVITY | CORNELL UNIVERSITY | 2019-03-21 | — | — | US | claimed |
| US-7727692-B2 | Electrophotographic photoreceptor, image forming apparatus, and process cartridge | FUJI XEROX CO., LTD. (JP) | 2010-06-01 | — | — | US | claimed |
| US-20080166615-A1 | COOLING LIQUID COMPOSITION FOR FUEL CELL | SHISHIAI-KABUSHIKIGAISHA (JP) | 2008-07-10 | — | — | US | claimed |
| US-20060145120-A1 | Cooling liquid composition for fuel cell | SHISHIAI-KABUSHIKIGAISHA (JP) | 2006-07-06 | — | — | US | claimed |
| EP-1653544-A1 | COOLING LIQUID COMPOSITION FOR FUEL CELL | Shishiai-Kabushikigaisha (JP) | 2006-05-03 | — | — | EP | claimed |
| US-4939279-A | Leukotriene antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1990-07-03 | — | — | US | claimed |
| US-4937253-A | LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1990-06-26 | — | — | US | claimed |
| EP-0202759-B1 | LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1990-06-20 | — | — | EP | claimed |
| EP-0365149-A2 | Leukotriene antagonist prodrugs | SMITHKLINE BEECHAM CORPORATION (US) | 1990-04-25 | — | — | EP | claimed |
| EP-0358240-A2 | Intermediates for the preparation of leukotriene antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1990-03-14 | — | — | EP | claimed |
| US-4874792-A | RESPIRATORY SYSTEM DISORDERS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-10-17 | — | — | US | claimed |
| EP-0313697-A1 | Leukotriene antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1989-05-03 | — | — | EP | claimed |
| US-4820719-A | ANTIALLERGENS, ANTIINFLAMMATORY, ANTIISCHEMIC AND HYPOTENSIVE AGENTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-04-11 | — | — | US | claimed |
| EP-0202759-A2 | Leukotriene antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1986-11-26 | — | — | EP | claimed |
| US-4400550-A | Synthesis of the navel orange worm pheromone (Z,Z)-11,13-hexadecadienal | ALBANY INTERNATIONAL CORP. (US) | 1983-08-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11198898-B2 | Chemical tools for imaging phospholipase D activity | PLD1, PLD2, PLD4 | HSD17B10 1191/4885MAPT 4383/4885CYP1A2 2481/4885 |
| US-20190085373-A1 | CHEMICAL TOOLS FOR IMAGING PHOSPHOLIPASE D ACTIVITY | PLD1, PLD2, PLD4 | HSD17B10 1191/4885MAPT 4383/4885CYP1A2 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.